Biosimilar May Be As Effective as Trastuzumab for Early Breast Cancer — Physician’s First Watch

Medical News |
June 5, 2017

Biosimilar May Be As Effective as Trastuzumab for Early Breast Cancer

By Kelly Young

Edited by Susan Sadoughi, MD, and André Sofair, MD, MPH

Biosimilar trastuzumab appears to have a similar effect on HER2-positive, early-stage breast cancer as standard trastuzumab (Herceptin), according to a study in Lancet Oncology that was presented at the American Society of Clinical Oncology's annual meeting.

Roughly 550 patients with HER2-positive, operable, early-stage breast cancer were randomized to receive either neoadjuvant trastuzumab or the trastuzumab biosimilar known as CT-P6 for 24 weeks. All patients also received neoadjuvant docetaxel, fluorouracil, epirubicin, and cyclophosphamide.

Rates of pathological complete response at the time of surgery were similar in the per-protocol analysis (47% for CT-P6 vs. 50% for reference trastuzumab). Adverse event rates were also similar.

The authors note that trastuzumab can cost up to $70,000, so a less expensive alternative would be welcome.

Your Comment

(will not be published)

Filtered HTML

  • Allowed HTML tags: <a> <em> <strong> <cite> <blockquote> <code> <ul> <ol> <li> <dl> <dt> <dd>
  • Web page addresses and e-mail addresses turn into links automatically.
  • Lines and paragraphs break automatically.

Plain text

  • No HTML tags allowed.
  • Web page addresses and e-mail addresses turn into links automatically.
  • Lines and paragraphs break automatically.
Do you have any conflict of interest to disclose?
CAPTCHA
This question is for testing whether you are a human visitor and to prevent automated spam submissions.

Vertical Tabs

* Required

Reader comments are intended to encourage lively discussion of clinical topics with your peers in the medical community. We ask that you keep your remarks to a reasonable length, and we reserve the right to withhold publication of remarks that do not meet this standard.

PRIVACY: We will not use your email address, submitted for a comment, for any other purpose nor sell, rent, or share your e-mail address with any third parties. Please see our Privacy Policy.